Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KDNY Chinook Therapeutics (KDNY) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Chinook Therapeutics Stock (NASDAQ:KDNY) 30 days 90 days 365 days Advanced Chart Ad InvestorPlaceBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.Go here now for this breaking story. Get Chinook Therapeutics alerts:Sign Up Key Stats Today's Range$40.39▼$40.3950-Day Range$38.66▼$40.3952-Week Range$18.34▼$40.51VolumeN/AAverage Volume1.19 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.Read More… Bigger Than Nvidia? (Ad)Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.Go here now for this breaking story. Receive KDNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KDNY Stock News HeadlinesChinook, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 21, 2024 | yahoo.comThree Finalists Announced for the 2024 Bloom Burton AwardApril 21, 2024 | finance.yahoo.comBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that's all they'll talk about.October 10, 2024 | InvestorPlace (Ad)Chinook ElementaryNovember 1, 2023 | usnews.comWedbush Downgrades Chinook Therapeutics (KDNY)August 8, 2023 | msn.comChinook Therapeutics, Inc. (KDNY)August 2, 2023 | uk.finance.yahoo.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | markets.businessinsider.comWells Fargo Downgrades Chinook Therapeutics (KDNY)August 1, 2023 | msn.comSee More Headlines KDNY Stock Analysis - Frequently Asked Questions How were Chinook Therapeutics' earnings last quarter? Chinook Therapeutics, Inc. (NASDAQ:KDNY) posted its earnings results on Tuesday, May, 9th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.03. Chinook Therapeutics's revenue for the quarter was down 32.2% on a year-over-year basis. What other stocks do shareholders of Chinook Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR). Company Calendar Last Earnings5/09/2023Today10/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:KDNY CUSIPN/A CIK1435049 Webchinooktx.com Phone(206) 485-7241FaxN/AEmployees214Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-187,870,000.00 Net Margins-4,199.93% Pretax Margin-4,115.56% Return on Equity-58.28% Return on Assets-44.72% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$6.13 million Price / Sales473.15 Cash FlowN/A Price / Cash FlowN/A Book Value$6.91 per share Price / Book5.85Miscellaneous Outstanding Shares71,810,000Free Float59,749,000Market Cap$2.90 billion OptionableOptionable Beta0.34 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:KDNY) was last updated on 10/10/2024 by MarketBeat.com Staff From Our PartnersPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dav...American Hartford Gold Group | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredBigger Than Nvidia?Bigger Than Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the n...InvestorPlace | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chinook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.